Evidence map›Paper›PMID 31925667›Full record

ReviewCurrent heart failure reports2020

Heart Failure With Mid-range Ejection Fraction.

Pratyaksh K Srivastava, Jeffrey J Hsu, Boback Ziaeian, Gregg C Fonarow

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current heart failure reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. miRNAs in Heart Development and Disease.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Observational
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Angiotensin receptor blocker neprilysin inhibitors.World journal of cardiology · 2021
    Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pratyaksh K SrivastavaDivision of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jeffrey J HsuDivision of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Boback ZiaeianDivision of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Gregg C FonarowDivision of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. gfonarow@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
American Heart Association-American Stroke Association 17SDG33630113NCATS NIH HHS KL2 TR001882
6 · The paper itself

Abstract

purpose of reviewTo describe the epidemiology, pathophysiology, management, and prognosis of patients with heart failure with mid-range ejection fraction (HFmrEF). RECENT

findingsIn 2013, The American Heart Association (AHA)/American College of Cardiology (ACC) assigned an ejection fraction (EF) range to heart failure with reduced ejection fraction (HFrEF, EF ≤ 40%) and heart failure with preserved ejection fraction (HFpEF, EF ≥50%). This classification created a "gray zone" of patients with EFs between 41% and 49% that ultimately came to be known as heart failure with borderline or mid-range ejection fraction. HFmrEF patients represent a group with heterogeneous clinical characteristics that at times resembles HFrEF, at others HFpEF, and at others still a unique phenotype altogether. No randomized controlled trials exist in those with HFmrEF, though HFrEF and HFpEF studies that include overlap suggest some potential benefit of beta blockers, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitors. Mortality rates among the HFmrEF population are significant, and are similar to those in patients with HFrEF and HFpEF. HFmrEF is a complex disorder that remains poorly understood. Future research is needed to better elucidate the pathophysiology, management, and prognosis of this condition.

Indexed as

Disease ManagementRegistriesGlobal HealthHeart FailureHumansMorbidityPrognosisRisk FactorsStroke VolumeHeart failureMid-range ejection fraction

Identifiers

PMID31925667
PMCPMC7652387
OpenAlexW2999947023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.